ArticlePharmacology research & perspectives2026
An Evaluation of Foreign Clinical Data in the Approval Reviews of Antimicrobial Medicines in Japan: Considering Ethnic and Regional Differences in Data Extrapolations in Accordance With Regulatory Circumstances.
Article in Pharmacology research & perspectives, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
The approval requirements in new regions that do not require domestic clinical data and the clinical data evaluation of multi-regional clinical trials (MRCTs) and foreign clinical trials (FCTs) in the Japanese approval review processes for antimicrobial medicines were explored. Foreign clinical data has been used to evaluate the efficacy of more than 60% (45/70) of approved antimicrobial drugs in Japan. Two FCT extrapolations based on bridging strategies were used for antimicrobial medicine approvals in the early 2000s after the issuance of International Council for Harmonization-Efficacy Guideline 5 (ICH-E5), but 40 approvals extrapolated efficacy evaluations from outside of Japan without bridging studies. Participation in MRCTs has increased since the 2010s, following Japan's notification "Basic Principles on Global Clinical Trials" for global clinical trials in 2007. From the commencement of the use of FCT extrapolations, comparisons of pharmacokinetic data have been used to examine regional differences. As experience with inter-regional data interpretation increases, similarities in the drug susceptibilities of infectious agents (pharmacodynamic data) and the medical environment (extrinsic factors) are being examined. In one approval in Japan, a different dose was set compared with that approved overseas because of differences in pharmacokinetics. We demonstrated that MRCTs and FCTs of antimicrobial medicines have been accepted as confirmatory trials in Japan without the need for bridging studies, which has been enabled by examining regional differences using pharmacokinetic data and additional comparisons of pharmacodynamic data and extrinsic factors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.